Johnson & Johnson

JNJ-N

NYSE:JNJ

164.81
3.08 (1.90%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
January 8, 2021
(A Top Pick Dec 16/19, Up 16%) Has gained some altitude. There has been no shortage of negative headlines over the years. Pharmaceuticals is a litigious industry in general. A well diversified company. A slower growth pharma company. However, it is a wonderful company looking at durability. Valuation is just above their buy price of $148. Would wait for a pullback to enter.
Show full opinionHide full opinion
(A Top Pick Dec 16/19, Up 16%) Has gained some altitude. There has been no shortage of negative headlines over the years. Pharmaceuticals is a litigious industry in general. A well diversified company. A slower growth pharma company. However, it is a wonderful company looking at durability. Valuation is just above their buy price of $148. Would wait for a pullback to enter.
BUY
BUY
January 4, 2021
Biden will protect Obamacare, which spells great news managed care companies. Healthcare will continue to be a major theme this year. JNJ especially is well-positioned for earnings, new products and their eventual vaccine.
Show full opinionHide full opinion
Biden will protect Obamacare, which spells great news managed care companies. Healthcare will continue to be a major theme this year. JNJ especially is well-positioned for earnings, new products and their eventual vaccine.
DON'T BUY
DON'T BUY
December 7, 2020
The healthcare sector in general has been in the news a lot recently. He owned this one a couple of years ago. It is a diversified, broad exposure to pharma. There are, however, sectors of healthcare he likes better such as managed health care and devices.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
December 7, 2020
The healthcare sector in general has been in the news a lot recently. He owned this one a couple of years ago. It is a diversified, broad exposure to pharma. There are, however, sectors of healthcare he likes better such as managed health care and devices.
BUY
BUY
November 30, 2020
It's fine. A cheap stock that will benefit from a weaker US dollar.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
November 30, 2020
It's fine. A cheap stock that will benefit from a weaker US dollar.
BUY
BUY
November 27, 2020

He bought it to increase his healthcare holdings. They have several business: prescriptions, medical devices, a huge consumer business, and vaccines. He's waiting for med. devices to pick up after operations resume globally after Covid. JNJ and Merck seem to lag the others in vaccines, but there'll be many opportunities to sell vaccines--vaccines will be a big winner for JNJ.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
November 27, 2020

He bought it to increase his healthcare holdings. They have several business: prescriptions, medical devices, a huge consumer business, and vaccines. He's waiting for med. devices to pick up after operations resume globally after Covid. JNJ and Merck seem to lag the others in vaccines, but there'll be many opportunities to sell vaccines--vaccines will be a big winner for JNJ.

DON'T BUY
DON'T BUY
November 19, 2020

Looking at the technical structure of the stock, the 200-day moving average has been moving sideways. We are not seeing growth, similarly to Pfizer. There is a 5-6% growth rate but paying 17x forward price earnings. A good quality name but there is not enough growth.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
November 19, 2020

Looking at the technical structure of the stock, the 200-day moving average has been moving sideways. We are not seeing growth, similarly to Pfizer. There is a 5-6% growth rate but paying 17x forward price earnings. A good quality name but there is not enough growth.

HOLD
HOLD
October 27, 2020
Allan Tong’s Discover Picks Bulls points to a robust balance sheet and a dividend that has risen for 50 straight years. JNJ is more diversified than its peers, operating in consumer products, diagnostics (for surgeries which have been rebounding since the spring lockdown) as well as drugs. It also trades at a reasonable 22.5x PE and pays a 2.78% dividend. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 27, 2020
Allan Tong’s Discover Picks Bulls points to a robust balance sheet and a dividend that has risen for 50 straight years. JNJ is more diversified than its peers, operating in consumer products, diagnostics (for surgeries which have been rebounding since the spring lockdown) as well as drugs. It also trades at a reasonable 22.5x PE and pays a 2.78% dividend. Read 3 Promising Diversified Coronavirus Vaccine Stocks Ahead of the Game: Fall Update for our full analysis.
TOP PICK
TOP PICK
October 26, 2020
It has three businesses – Pharma, devices and personal care. It is a great story because if one is doing poorly, the other two aren’t. 16 times earnings and a great increasing, dividend for 54 years in a row. They are working on a COVID vaccine.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 26, 2020
It has three businesses – Pharma, devices and personal care. It is a great story because if one is doing poorly, the other two aren’t. 16 times earnings and a great increasing, dividend for 54 years in a row. They are working on a COVID vaccine.
DON'T BUY
DON'T BUY
October 23, 2020

One of the companies going through a vaccine trial. They were in the news recently because they had to pause trials due to an illness in a test participant. However, it is not just about the vaccine. They have consumer, pharma and medical device. There is still litigation list from the talc issue. It trades at 15x earnings, which is reasonable but it does take into account vulnerabilities. He prefers BDX.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 23, 2020

One of the companies going through a vaccine trial. They were in the news recently because they had to pause trials due to an illness in a test participant. However, it is not just about the vaccine. They have consumer, pharma and medical device. There is still litigation list from the talc issue. It trades at 15x earnings, which is reasonable but it does take into account vulnerabilities. He prefers BDX.

HOLD
HOLD
October 15, 2020

JNJ vs. ABT Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
October 15, 2020

JNJ vs. ABT Similar businesses. You absolutely need exposure to healthcare. He holds JNJ for the dividend aristocrat qualities. ABT has been impressive. Testing platform has been phenomenal and will continue to ramp up. It's a great addition to portfolios at these levels. Tough choice between the two, but ABT probably has more immediate upside.

DON'T BUY
DON'T BUY
October 9, 2020
They boast a great pipeline of drugs that it overshadows their Covid efforts. Problem is the stock jumped above $150 ahead of next week's quarterly report--the bar has been raised, but he prefers lower expectations.
Show full opinionHide full opinion
They boast a great pipeline of drugs that it overshadows their Covid efforts. Problem is the stock jumped above $150 ahead of next week's quarterly report--the bar has been raised, but he prefers lower expectations.
PAST TOP PICK
PAST TOP PICK
October 5, 2020
(A Top Pick Oct 15/19, Up 14%) His model price is $201 or a 37% upside. They are in phase three trials with a COVID-19 vaccine.
Show full opinionHide full opinion
(A Top Pick Oct 15/19, Up 14%) His model price is $201 or a 37% upside. They are in phase three trials with a COVID-19 vaccine.
TOP PICK
TOP PICK
September 29, 2020
Stockchase Research Editor: Michael O'Reilly In the search for a pandemic vaccine, JNJ is a potential winner. Leveraging off their proven technology with their Ebola, HIV and other vaccines, the company continues to develop a COVID-19 vaccine that presently shows strong immunity response in 99% of trials. It is also the only option that is testing a single-dose vaccine. Revenues have dipped 10% in the latest quarterly earnings, but that can be attributed to a slow down in elective procedures. It pays a good dividend backed by a 67% payout ratio. We would trade this with a stop-loss at $132. Yield 2.75% (Analysts’ price target is $165.06)
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
September 29, 2020
Stockchase Research Editor: Michael O'Reilly In the search for a pandemic vaccine, JNJ is a potential winner. Leveraging off their proven technology with their Ebola, HIV and other vaccines, the company continues to develop a COVID-19 vaccine that presently shows strong immunity response in 99% of trials. It is also the only option that is testing a single-dose vaccine. Revenues have dipped 10% in the latest quarterly earnings, but that can be attributed to a slow down in elective procedures. It pays a good dividend backed by a 67% payout ratio. We would trade this with a stop-loss at $132. Yield 2.75% (Analysts’ price target is $165.06)
TOP PICK
TOP PICK
September 24, 2020
Raised dividend for 57 years. Nice balance between drug business, consumer products, and diagnostics. Likely to see acquisitions in consumer and diagnostics. A beneficiary of the post-Covid environment. Long-term exposure to a global healthcare leader. Good valuation. Continued performance. Yield is 2.08%. (Analysts’ price target is $163.63)
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
September 24, 2020
Raised dividend for 57 years. Nice balance between drug business, consumer products, and diagnostics. Likely to see acquisitions in consumer and diagnostics. A beneficiary of the post-Covid environment. Long-term exposure to a global healthcare leader. Good valuation. Continued performance. Yield is 2.08%. (Analysts’ price target is $163.63)
BUY WEAKNESS
BUY WEAKNESS
September 23, 2020
Just announced it started its phase 3 trial of its Covid vaccine. JNJ offers real value. You can buy a tranche tomorrow then more if it goes down.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
September 23, 2020
Just announced it started its phase 3 trial of its Covid vaccine. JNJ offers real value. You can buy a tranche tomorrow then more if it goes down.
Showing 1 to 15 of 468 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 13

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 5

Total Signals / Votes : 20

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 20 stock analysts published opinions about JNJ-N. 13 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is PAST TOP PICK. Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by Chris Blumas on 2021-01-08. Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

20 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2021-01-22, Johnson & Johnson (JNJ-N) stock closed at a price of $164.81.